Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Amgen

Amgen: How To Find And Own America's Greatest Opportunities

From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more than 50 times.

Investors Business Daily

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Investors Business Daily

Career blocks for female scientists put under scrutiny

Talented female scientists are being pushed out of cancer research due to gender discrimination, ageism and an absence of mentorship, funding and job security.

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

Microsoft Copilot is "pretty important" but customers still prefer ChatGPT — "OpenAI has done a tremendous job"

A new report suggests that Microsoft's sales division is struggling to differentiate Copilot from ChatGPT, with customers preferring OpenAI's offering.

Windows Central

New once-a-month drug could treat diabetes and obesity, scientists say

Researchers say experimental drug’s less frequent dosing could improve adherence and offer long-term control

The Independent UK

Amgen Hammered As 'Tough' Obesity Meeting Reminds It It's Not The Incumbent

Amgen presented promising results for its weight-loss drug. But not everyone is convinced.

Investors Business Daily

How Is Amgen's Stock Performance Compared to Other Pharmaceuticals Stocks?

Amgen has underperformed the Pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

The Next Look At Amgen's Obesity Drug Is Coming. Here's What Investors Are Watching.

Later this month, the Street will have a fresh opportunity to gauge the potential for Amgen's experimental weight-loss drug, MariTide.

Investors Business Daily

Stock Market Today: Nasdaq Outperforms as Big Tech Rallies

The Dow Jones Industrial Average closed lower for a second day as Amgen and Merck fell.

Kiplinger

S&P, Dow Pharma Stocks Boomerang On Drug-Pricing Order That Is 'All Bark' And 'Little Bite'

Pharmaceutical stocks boomeranged Monday after Trump signed an executive order tying drug prices in the U.S. to international price tags.

Investors Business Daily

12 Stocks Blow Away Warren Buffett's Long-Term Track Record

Warren Buffett's Berkshire Hathaway sports an enviable long-term track record. But not even Buffett is No. 1 in the S&P 500 in the long run.

Investors Business Daily

Amgen Stock Outlook: Is Wall Street Bullish or Bearish?

Although Amgen has lagged behind the broader market over the past year, Wall Street analysts remain cautiously optimistic about the company’s long-term outlook.

Barchart

Dow Jones Rallies On Surprise Jobs Report; Apple Dives On Earnings

The Dow Jones rallied Friday on a surprise April jobs report. Apple stock dived on earnings on the stock market today.

Investors Business Daily

3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.

MarketBeat

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Stocks Soar Before the Open on Upbeat Microsoft and Meta Results, More Big Tech Earnings on Tap

June S&P 500 E-Mini futures (ESM25) are up +1.18%, and June Nasdaq 100 E-Mini futures (NQM25) are up +1.68% this morning as forecast-beating quarterly results from Microsoft and Meta boosted sentiment.

Fortune

Elon Musk’s retreat from DOGE has lifted Tesla’s valuation by $158 billion—but the stock is still 50% off its peak

A TSLA stock rebound led to gains surpassing the current market caps of Amgen or Adobe.

Barchart

Analysts Think You Should Buy and Hold This 1 Dividend Stock ‘Forever’

Amgen stands out as a stable and attractive dividend stock, with a strong lineup of new medicines, a solid 3.45% forward yield, and a 201% dividend growth over the past decade.

Barchart

Amgen's Quarterly Earnings Preview: What You Need to Know

Amgen is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan

Pharma names whipsawed Wednesday after Trump said he would enact "major" tariffs on drug imports and then backed off his tariffs — for now.

Investors Business Daily

Apple And Meta Get Nixed — But Top Funds Binge On This Stock

While Megacaps Apple and Meta go AWOL, Netflix stock and insurance firms dominate new buys by the best mutual funds.

Investors Business Daily

Nvidia, Other Techs Hurt Dow Jones, But These Names Outperformed In Q1

Since it joined the Dow industrials on Nov. 7, Nvidia stock is down nearly 30%.

Barchart

These 2 Buy-Rated Dividend Stocks Could Be Next in Line for a Trump Tariff Selloff. Should You Jump Ship Now?

Trump’s proposed tariffs on pharmaceutical imports from countries like Ireland and India have sparked concerns for companies like Amgen and Gilead Sciences.

The Conversation

With 23andMe filing for bankruptcy, what happens to consumers’ genetic data?

The announcement that 23andMe is filing for bankruptcy and has put its genetic genealogy database up for sale has sent its customers into a bit of a privacy tizzy. On March 21, California Attorney General Bob Bonta issued a consumer alert with detailed instructions about how to delete one’s data.

Barchart

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Barchart

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Amgen has outperformed the healthcare sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations